Table 1 Baseline demographics, ventilatory status and routine laboratory parameters.

From: A randomised controlled trial of plasma exchange compared to standard of care in the treatment of severe COVID-19 infection (COVIPLEX)

 

SoC (n = 11)

PLEX (n = 11)

Age (years)

55 (42–69)

60 (56–65)

Gender (%male)

9 (82%)

9 (82%)

Ethnicity

 White

7 (64%)

4 (36%)

 Asian

1 (9%)

4 (36%)

 Black

2 (18%)

2 (18%)

 Other

1 (9%)

1 (9%)

Body mass index (kg m−2)

29 (25–32)

30 (28–33)

Smoker

 Never

6 (55%)

5 (45.5%)

 Ex

4 (36%)

5 (45.5%)

 Current

1 (9%)

1 (0%)

 Unknown

0 (0%)

1 (9%)

Co-morbid illness

 T2DM

3 (27%)

6 (45.5%)

 HTN

2 (18%)

7 (64%)

 IHD

1 (9%)

2 (18%)

Days symptoms to hospital admit

6 (4–10)

9 (7–10)

Vaccinated

1 (9%)

0 (0%)

COVID-19 variant

 Wild type

3 (27%)

3 (27%)

 Alpha (B.1.1.7)

7 (64%)

7 (55%)

 Delta (B.1.617.2)

1 (9%)

2 (18%)

Steroids

11 (100%)

11 (100%)

IL-6 inhibitor

4 (36%)

4 (36%)

Days Admit to PEX (or enrolment for SoC)

1 (1–4)

2 (1–3)

Days IL-6 inhibitor to PLEX (or enrolment for SoC)

0.5 (0–2)

1.5 (1–4.25)

Mode of ventilation Day 0

 Face mask

3 (27%)

2 (18%)

 HFNO

1 (9%)

3 (27%)

 NIPPV

6 (55%)

6 (55%)

IMV

1 (9%)

0 (0%)

  1. Demographics, treatment, and level of respiratory support in patients randomised to standard of care or plasma exchange. (T2DM: type 2 diabetes mellitus, HTN: hypertension, IHD: ischaemic heart disease, IL-6: interleukin- 6, PEX: plasma exchange, SoC: standard of care, HFNO: high flow nasal oxygen, NIPPV: non-invasive positive pressure ventilation, IMV: invasive mechanical ventilation). Continuous and categorical variables are reported as median (interquartile range) and n (%), respectively. Categorical data were compared using the chi-square test. Comparison of continuous data between PEX and SoC groups was performed using the Mann Whitney U tests.
Back to article page